# Temozolomide Chronotherapy for High Grade Glioma

> **NCT02781792** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 42 (actual)

## Conditions studied

- Glioma
- Glioblastoma Multiforme

## Interventions

- **DRUG:** Temozolomide
- **OTHER:** Functional Assessment of Cancer Therapy - Brain
- **OTHER:** ActTrust Condor Instrument Watch

## Key facts

- **NCT ID:** NCT02781792
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-11
- **Primary completion:** 2024-07-18
- **Final completion:** 2024-07-18
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02781792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02781792, "Temozolomide Chronotherapy for High Grade Glioma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02781792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*